Poland has grown into one of Europe's most commercially interesting medical cannabis markets for Canadian Licensed Producers, and it did so with very little of the noise that surrounds Germany. Roughly 105,000 patients filled cannabis prescriptions in 2025, and every gram they bought was imported. The country's 2025 import limit was 20 tonnes. Actual dispensing came in near 5,450 kg. That gap is supply headroom, and it belongs to exporters who can meet Polish documentation standards.
Exporting cannabis from Canada to Poland requires four things. You need a per-shipment export permit from Health Canada, a matching import permit from Poland's Chief Pharmaceutical Inspector (GIF), product made to EU-GMP standards, and a Polish marketing authorisation, either your own or your wholesale partner's. This guide covers the market data behind the opportunity, the regulators involved, the step-by-step permit chain, and the mistakes that stall first shipments. Our differentiated angle: most Canadian flower reaches Poland indirectly through Portugal, and we'll show you when direct supply beats that detour.
Poland's medical cannabis market in 2026
Poland runs a fully import-dependent model. A 2022 amendment to the Act on Counteracting Drug Addiction opened cultivation to research institutes under permit. Exactly one permit has been issued so far, to the Warsaw Institute of Biotechnology in December 2023. As of early 2026, no commercial-scale domestic production has reached pharmacy shelves. Every flower product a Polish patient buys crossed a border to get there.
The supply split matters to your strategy. About 68% of flower products arrive from Portugal and roughly 32% come directly from Canada. Those headline numbers understate Canada's real footprint. A large share of the Portuguese volume is Canadian-grown flower finished in Portugal, then often packaged in Germany before it reaches Warsaw. Canadian genetics already dominate Polish pharmacy shelves. The open question is whether your flower gets there under your own export permit or someone else's margin structure.
| Market indicator | 2025 figure |
|---|---|
| Active patients | Approximately 105,000 |
| Market size | Over 45 million euros |
| Annual import limit | 20 tonnes (20,000 kg) |
| Volume actually dispensed | Approximately 5,450 kg |
| Authorised flower products | Approximately 30 |
| Average pharmacy price | 12.80 to 13.80 euros per gram |
| Public reimbursement | None, patients pay out of pocket |
One more data point shapes demand forecasting. In November 2024, Poland's Ministry of Health restricted telemedicine prescribing and made initial exams in-person. Prescription volumes dropped hard, then recovered through 2025 as clinics absorbed patient flow. Poland is now the reference case European operators study for regulatory shock and recovery. The lesson for suppliers: demand here has proven resilient, not fragile.
Who regulates cannabis imports into Poland
Two statutes govern medical cannabis in Poland: the Act on Counteracting Drug Addiction and the Pharmaceutical Law Act, supported by Ministry of Health regulations. Three regulatory touchpoints matter to a Canadian exporter.
GIF: the permit issuer
The Chief Pharmaceutical Inspectorate (Glowny Inspektorat Farmaceutyczny) authorises companies to manufacture, process, import, and distribute medical cannabis. Polish importers need a standard business activity authorisation plus a narcotic authorisation from GIF. On top of those standing licences, GIF issues one-off permits for each specific import, export, or intra-community supply. Each permit fixes the volume and the time window for the movement. Nothing about the Polish side is reusable across shipments.
URPL: the product gatekeeper
Marketing authorisations come from the President of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL). Products are authorised as raw cannabis, which pharmacies compound into dispensed preparations. An authorisation lasts five years. Getting one typically takes over two years. That timeline drives most Canadian market-entry decisions, as we'll cover in the pathway below.
INCB: the quota ceiling
Poland's annual import volumes are capped through the estimates system run by the International Narcotics Control Board (INCB). GIF will only issue a one-off import licence while the national annual limit has room left. If you're new to how those national estimates work, our guide to INCB cannabis import quotas breaks down the cycle and its timing traps.
The 5-step Poland entry path for Canadian LPs
Here's the sequence a Canadian LP follows to land compliant flower in Poland. The two-permit logic will feel familiar if you've shipped to Germany or Australia. The Polish variation is how much weight falls on product registration.
- Step one: choose your registration route. You can pursue your own URPL marketing authorisation, a two-year-plus process, or supply a Polish wholesaler that already holds one. Most Canadian LPs start with an existing holder and revisit their own registration once volumes justify it.
- Step two: confirm quota room and secure the GIF import permit. Your Polish partner applies to GIF for a one-off import permit covering product, volume, and validity window. GIF grants it only if Poland's annual limit has headroom. The mechanics mirror the two-permit chain we've mapped in our guide to cannabis import permits.
- Step three: apply for the Health Canada export permit. Under the Cannabis Act, each shipment needs its own export permit. The application must match the Polish import permit on product, quantity, and consignee. Our walkthrough of the Health Canada cannabis export permit process covers the application package in detail.
- Step four: assemble the quality documentation. Polish pharmacy supply requires EU-GMP manufacturing standards and full analytical documentation. That means batch certificates of analysis, stability data, and a clear statement of irradiation status. Gaps here surface at the worst possible moment, during customs review.
- Step five: ship, reconcile, repeat. Clear Canadian export controls, clear Polish customs against the GIF permit, and reconcile shipped volumes against both permits. Every permit is one-off. Your next shipment restarts the chain, so build the permit cycle into your supply cadence.
What Polish importers expect from a Canadian supplier
Winning a Polish wholesale partner comes down to four things they'll test before any purchase order appears.
EU-GMP is the entry ticket, not a differentiator. Health Canada GMP documentation alone won't carry a Polish submission. Your batch release and site certification need to match European expectations from the first conversation. Analytical depth comes next. With only around 30 authorised flower products competing, wholesalers compare suppliers on COA completeness, batch-to-batch cannabinoid consistency, and cultivar continuity across reorders. A cultivar that drifts three points of THC between lots creates pharmacy-level complaints the wholesaler has to absorb.
Pricing discipline is the third test. Work backwards from the 12.80 to 13.80 euro per gram pharmacy average through wholesaler margin, compounding, and distribution. The landed prices you arrive at reward efficient producers, not premium-priced hopefuls. Global price compression has reached every import market, and Poland's out-of-pocket patients are price sensitive. The suppliers holding share are the ones whose quality justifies a defensible, not extravagant, price.
Finally, expect scrutiny of your routing choice. Supplying Poland directly avoids the margin stack of the Portugal processing detour, but you carry EU-GMP compliance and permit administration yourself. Shipping bulk to an EU processing partner spreads that burden at the cost of margin and brand visibility. The right answer depends on your volumes and certification status. It parallels the routing decision in our Canada to UK export guide.
AlphaLeaf is a Montreal-based Health Canada Licensed Producer of indoor-grown, hand-trimmed cannabis flower. We hold export authorisation under the Cannabis Act. We maintain ISO 17025 batch testing, full traceability records, and the EU-aligned quality documentation that Polish wholesalers and EU import partners require for pharmacy supply. If Poland is on your 2026 expansion map, or you're an importer weighing direct Canadian supply, talk to our export team about batch availability and documentation packages.
Frequently Asked Questions
Does Poland grow its own medical cannabis?
No commercial domestic production exists. A 2022 law allows research institutes to cultivate under permit, and only one permit has been issued, to the Warsaw Institute of Biotechnology in December 2023. As of early 2026, all cannabis dispensed in Polish pharmacies is imported.
What permits does a cannabis shipment from Canada to Poland need?
Each shipment needs two one-off permits: an import permit from Poland's Chief Pharmaceutical Inspector (GIF) obtained by the Polish importer, and a matching export permit from Health Canada under the Cannabis Act. Both fix the product, volume, and validity window, and neither can be reused.
Is EU-GMP mandatory for cannabis sold in Polish pharmacies?
Yes. Products supplied to Polish pharmacies must meet EU Good Manufacturing Practice standards and arrive with full quality and analytical documentation, including certificates of analysis. Health Canada GMP documentation alone is not sufficient for the Polish channel.
How much cannabis can Poland import each year?
Poland's annual import volume is capped through the INCB estimates system. The 2025 limit was 20 tonnes, while only about 5,450 kg was actually dispensed, leaving substantial headroom. GIF issues import permits only while the annual limit has room remaining.
How long does Polish product registration take?
A marketing authorisation from URPL, the Office for Registration of Medicinal Products, typically takes over two years to obtain and is valid for five years. Most Canadian LPs enter Poland by supplying a wholesaler that already holds an authorisation rather than waiting out their own registration.
